Pulmonary Hypertension - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：69頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Pulmonary Hypertension - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Pulmonary Hypertension - Pipeline Review, H1 2014’, provides an overview of the Pulmonary Hypertension’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pulmonary Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Pulmonary Hypertension - Pipeline Review, H1 2014’, provides an overview of the Pulmonary Hypertension’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Pulmonary Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Hypertension and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Pulmonary Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Pulmonary Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Pulmonary Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Pulmonary Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Pulmonary Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Pulmonary Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pulmonary Hypertension Overview 8
Therapeutics Development 9
Pipeline Products for Pulmonary Hypertension - Overview 9
Pipeline Products for Pulmonary Hypertension - Comparative Analysis 10
Pulmonary Hypertension - Therapeutics under Development by Companies 11
Pulmonary Hypertension - Therapeutics under Investigation by Universities/Institutes 13
Pulmonary Hypertension - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Pulmonary Hypertension - Products under Development by Companies 18
Pulmonary Hypertension - Products under Investigation by Universities/Institutes 19
Pulmonary Hypertension - Companies Involved in Therapeutics Development 20
Sanofi 20
Activaero GmbH 21
Silence Therapeutics plc 22
Bayer AG 23
Ikaria Inc. 24
Proreo Pharma AG 25
Vicore Pharma AB 26
Pulmonary Hypertension - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Nepolong - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug 1 For Pulmonary Hypertension - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
IK-3001 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
atorvastatin calcium - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
IK-7002 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
riociguat - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
anakinra - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SAR-407899 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SAR-164653 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
C-21 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drug-2 For Pulmonary Hypertension - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
DACC Programs For Lung Diseases - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Peptide to Inhibit NADPH Oxidase for Pulmonary Hypertension - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
R-100 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Drug for Pulmonary Hypertension - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MetAP-II Inhibitors - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Pulmonary Hypertension - Recent Pipeline Updates 58
Pulmonary Hypertension - Dormant Projects 64
Pulmonary Hypertension - Product Development Milestones 65
Featured News & Press Releases 65
Jan 24, 2014: Bayer’s Riociguat Recommended for Approval in the EU in Two Forms of Pulmonary Hypertension 65
Jul 24, 2013: New England Journal of Medicine Publishes Results of Two Pivotal Phase III Studies of Bayer’s Riociguat 66
Nov 15, 2012: Vicore Pharma Announces Presentation Of Study Results Of C21 In Pulmonary Hypertension At 2012 American Heart Meeting 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69
List of Tables
Number of Products under Development for Pulmonary Hypertension, H1 2014 9
Number of Products under Development for Pulmonary Hypertension - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Pulmonary Hypertension - Pipeline by Sanofi, H1 2014 20
Pulmonary Hypertension - Pipeline by Activaero GmbH, H1 2014 21
Pulmonary Hypertension - Pipeline by Silence Therapeutics plc, H1 2014 22
Pulmonary Hypertension - Pipeline by Bayer AG, H1 2014 23
Pulmonary Hypertension - Pipeline by Ikaria Inc., H1 2014 24
Pulmonary Hypertension - Pipeline by Proreo Pharma AG, H1 2014 25
Pulmonary Hypertension - Pipeline by Vicore Pharma AB, H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Pulmonary Hypertension Therapeutics - Recent Pipeline Updates, H1 2014 58
Pulmonary Hypertension - Dormant Projects, H1 2014 64
List of Figures
Number of Products under Development for Pulmonary Hypertension, H1 2014 9
Number of Products under Development for Pulmonary Hypertension - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Pulmonary Hypertension Overview 8
Therapeutics Development 9
Pipeline Products for Pulmonary Hypertension - Overview 9
Pipeline Products for Pulmonary Hypertension - Comparative Analysis 10
Pulmonary Hypertension - Therapeutics under Development by Companies 11
Pulmonary Hypertension - Therapeutics under Investigation by Universities/Institutes 13
Pulmonary Hypertension - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Pulmonary Hypertension - Products under Development by Companies 18
Pulmonary Hypertension - Products under Investigation by Universities/Institutes 19
Pulmonary Hypertension - Companies Involved in Therapeutics Development 20
Sanofi 20
Activaero GmbH 21
Silence Therapeutics plc 22
Bayer AG 23
Ikaria Inc. 24
Proreo Pharma AG 25
Vicore Pharma AB 26
Pulmonary Hypertension - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Target 28
Assessment by Mechanism of Action 31
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
Nepolong - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug 1 For Pulmonary Hypertension - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
IK-3001 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
atorvastatin calcium - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
IK-7002 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
riociguat - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
anakinra - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SAR-407899 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
SAR-164653 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
C-21 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Drug-2 For Pulmonary Hypertension - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
DACC Programs For Lung Diseases - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Peptide to Inhibit NADPH Oxidase for Pulmonary Hypertension - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
R-100 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Drug for Pulmonary Hypertension - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MetAP-II Inhibitors - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
Pulmonary Hypertension - Recent Pipeline Updates 58
Pulmonary Hypertension - Dormant Projects 64
Pulmonary Hypertension - Product Development Milestones 65
Featured News & Press Releases 65
Jan 24, 2014: Bayer’s Riociguat Recommended for Approval in the EU in Two Forms of Pulmonary Hypertension 65
Jul 24, 2013: New England Journal of Medicine Publishes Results of Two Pivotal Phase III Studies of Bayer’s Riociguat 66
Nov 15, 2012: Vicore Pharma Announces Presentation Of Study Results Of C21 In Pulmonary Hypertension At 2012 American Heart Meeting 67
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 69
Disclaimer 69
List of Tables
Number of Products under Development for Pulmonary Hypertension, H1 2014 9
Number of Products under Development for Pulmonary Hypertension - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Pulmonary Hypertension - Pipeline by Sanofi, H1 2014 20
Pulmonary Hypertension - Pipeline by Activaero GmbH, H1 2014 21
Pulmonary Hypertension - Pipeline by Silence Therapeutics plc, H1 2014 22
Pulmonary Hypertension - Pipeline by Bayer AG, H1 2014 23
Pulmonary Hypertension - Pipeline by Ikaria Inc., H1 2014 24
Pulmonary Hypertension - Pipeline by Proreo Pharma AG, H1 2014 25
Pulmonary Hypertension - Pipeline by Vicore Pharma AB, H1 2014 26
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Stage and Target, H1 2014 30
Number of Products by Stage and Mechanism of Action, H1 2014 33
Number of Products by Stage and Route of Administration, H1 2014 35
Number of Products by Stage and Molecule Type, H1 2014 37
Pulmonary Hypertension Therapeutics - Recent Pipeline Updates, H1 2014 58
Pulmonary Hypertension - Dormant Projects, H1 2014 64
List of Figures
Number of Products under Development for Pulmonary Hypertension, H1 2014 9
Number of Products under Development for Pulmonary Hypertension - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 27
Number of Products by Top 10 Target, H1 2014 28
Number of Products by Stage and Top 10 Target, H1 2014 29
Number of Products by Top 10 Mechanism of Action, H1 2014 31
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 32
Number of Products by Top 10 Route of Administration, H1 2014 34
Number of Products by Stage and Top 10 Route of Administration, H1 2014 35
Number of Products by Top 10 Molecule Type, H1 2014 36
Number of Products by Stage and Top 10 Molecule Type, H1 2014 37
